JNJ

229.41

+0.89%↑

ISRG

499.72

-0.78%↓

ABT

109.65

+0.38%↑

RDY

13.46

+0.45%↑

NEOG

10.44

+2.25%↑

JNJ

229.41

+0.89%↑

ISRG

499.72

-0.78%↓

ABT

109.65

+0.38%↑

RDY

13.46

+0.45%↑

NEOG

10.44

+2.25%↑

JNJ

229.41

+0.89%↑

ISRG

499.72

-0.78%↓

ABT

109.65

+0.38%↑

RDY

13.46

+0.45%↑

NEOG

10.44

+2.25%↑

JNJ

229.41

+0.89%↑

ISRG

499.72

-0.78%↓

ABT

109.65

+0.38%↑

RDY

13.46

+0.45%↑

NEOG

10.44

+2.25%↑

JNJ

229.41

+0.89%↑

ISRG

499.72

-0.78%↓

ABT

109.65

+0.38%↑

RDY

13.46

+0.45%↑

NEOG

10.44

+2.25%↑

Home・Akcijų sąrašas・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

4.23 0.95

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.08

Max

4.24

Pagrindiniai rodikliai
By Trading Economics
Pajamos	9.6M -162M
Pardavimai	-14M 5.2M
Pelno marža	-3,135.324
Darbuotojai	800
EBITDA	6.4M -141M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+84.96% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-27

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	18M 2.4B
Ankstesnė atidarymo kaina	3.28
Ankstesnė uždarymo kaina	4.23

Naujienos nuotaikos

By Acuity

50%

131 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

4.15 / 4.75 Palaikymas ir pasipriešinimas

Recursion Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-01 23:59; UTC

Rinkos pokalbiai

Oil Prices Fall Amid Signs of U.S.-Iran Negotiations -- Market Talk

2026-02-01 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

2026-02-01 23:44; UTC

Rinkos pokalbiai

Gold Falls as Markets Further Price in Warsh-Led Fed -- Market Talk

2026-02-01 12:47; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Led Group Set to Buy Singapore Data-Center Firm Valued at Over $10 Billion -- Update

2026-02-01 03:02; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Led Group Set to Buy Singapore Data-Center Firm Valued at Over $10 Billion

2026-02-01 03:01; UTC

Įsigijimai, susijungimai, perėmimai

KKR Consortium Currently Owns Near 20% Stake in STT GDC

2026-02-01 03:01; UTC

Įsigijimai, susijungimai, perėmimai

KKR Consortium Acquiring Remaining Stake in STT GDC With Singtel, Sources Say

2026-01-31 18:48; UTC

Įsigijimai, susijungimai, perėmimai

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- Update

2026-01-31 16:40; UTC

Uždarbis

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

2026-01-31 09:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

2026-01-30 23:41; UTC

Rinkos pokalbiai

Deckers Outdoor Seen as Undervalued -- Market Talk

2026-01-30 23:12; UTC

Įsigijimai, susijungimai, perėmimai

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

2026-01-30 22:20; UTC

Uždarbis

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

2026-01-30 22:10; UTC

Rinkos pokalbiai

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

2026-01-30 21:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-01-30 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-30 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-30 21:42; UTC

Uždarbis

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

2026-01-30 21:36; UTC

Uždarbis

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

2026-01-30 21:33; UTC

Uždarbis

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

2026-01-30 20:42; UTC

Uždarbis

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

2026-01-30 20:37; UTC

Įsigijimai, susijungimai, perėmimai

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

Akcijų palyginimas

Kainos pokytis

Recursion Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

84.96% į viršų

12 mėnesių prognozė

Vidutinis 7.75 USD 84.96%

Aukščiausias 11 USD

Žemiausias 5 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Recursion Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Recursion Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

4.15 / 4.75Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

131 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.